|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0002844,
umls-concept:C0030705,
umls-concept:C0038952,
umls-concept:C0067685,
umls-concept:C0087111,
umls-concept:C0138741,
umls-concept:C0205160,
umls-concept:C0205195,
umls-concept:C0205474,
umls-concept:C0229664,
umls-concept:C0332206,
umls-concept:C0376358,
umls-concept:C0392752,
umls-concept:C0442805,
umls-concept:C0599161,
umls-concept:C1310550,
umls-concept:C1333570,
umls-concept:C1446409,
umls-concept:C1511790,
umls-concept:C1519595,
umls-concept:C1880198
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2007-10-31
|
|
pubmed:abstractText |
The clinical relevance of positive molecular staging as defined by reverse transcriptase-polymerase chain reaction (RT-PCR) detections of both prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts in the peripheral blood (PB) of patients with prostate cancer is still debatable.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1434-6621
|
|
pubmed:author |
pubmed-author:BogdanosJohnJ,
pubmed-author:DardoufasConstantineC,
pubmed-author:DimopoulosTheodorosT,
pubmed-author:HalapasAntonisA,
pubmed-author:KoutsilierisMichaelM,
pubmed-author:LembessisPeterP,
pubmed-author:MaragoudakisEvangelosE,
pubmed-author:MilathianakisConstantineC,
pubmed-author:MsaouelPavlosP,
pubmed-author:PanteleakouZacharoulaZ,
pubmed-author:PapaioannouAndreasA,
pubmed-author:PissimissisNikolaosN,
pubmed-author:SourlaAntigoneA
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
45
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1488-94
|
|
pubmed:meshHeading |
pubmed-meshheading:17924845-Aged,
pubmed-meshheading:17924845-Androgen Antagonists,
pubmed-meshheading:17924845-Antigens, Surface,
pubmed-meshheading:17924845-Disease-Free Survival,
pubmed-meshheading:17924845-Glutamate Carboxypeptidase II,
pubmed-meshheading:17924845-Humans,
pubmed-meshheading:17924845-Male,
pubmed-meshheading:17924845-Middle Aged,
pubmed-meshheading:17924845-Prospective Studies,
pubmed-meshheading:17924845-Prostate-Specific Antigen,
pubmed-meshheading:17924845-Prostatic Neoplasms,
pubmed-meshheading:17924845-RNA, Messenger,
pubmed-meshheading:17924845-Reverse Transcriptase Polymerase Chain Reaction
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy.
|
|
pubmed:affiliation |
Department of Experimental Physiology, National and Kapodistrian University of Athens, Athens, Greece.
|
|
pubmed:publicationType |
Journal Article
|
